GlobeNewswire Inc | Dec 22, 2021 08:30AM EST

December 22, 2021

NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acers management team will participate in the upcoming 11th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright BioConnect Virtual Conference.

Conference: 11^th Annual LifeSci Partners Corporate Access virtual eventFormat: One-on-one virtual meetingsDates: January 5-7, 2022Register: https://www.meetmax.com/sched/event_78427/invitee_login.html Conference: H.C. Wainwright Global BioConnect Virtual ConferenceFormat: On-demand recorded corporate presentationDates: January 10, 2022Webcast: https://journey.ct.events/view/b30c9e23-05f3-4bc7-8e05-675b2cfa5a88

About Acer Therapeutics Inc.Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acers pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. In March 2021, Acer entered into a Collaboration and License Agreement with Relief for development and commercialization of ACER-001. For more information, visit www.acertx.com.

Investor Contact:Hans VitzthumLifeSci AdvisorsPh: 617-430-7578hans@lifesciadvisors.com

Jim DeNikeAcer Therapeutics Inc.Ph: 844-902-6100jdenike@acertx.com